Evidence map›Paper›PMID 37033542›Full record

ArticleCureus2023

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome.

Farhan Azad, Clive J Miranda, Al Amin, Ruhi Hadwani, Matthew Gravina

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Farhan AzadInternal Medicine, University at Buffalo, Buffalo, USA.
Clive J MirandaInternal Medicine, University at Buffalo, Buffalo, USA.
Al AminPathology, University at Buffalo, Buffalo, USA.
Ruhi HadwaniPathology, University at Buffalo, Buffalo, USA.
Matthew GravinaHematology and Medical Oncology, University at Buffalo, Buffalo, USA.
Buffalo General Medical Center · USUniversity at Buffalo, State University of New York · USBuffalo Medical Group · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.

Indexed as

cholangiocarcinomacisplatineculizumabgemcitabineklatskinuremic

Identifiers

PMID37033542
PMCPMC10078131
OpenAlexW4323353576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.